Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | +5.05% | +6.71% | +31.31% |
05-13 | Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating | MT |
05-09 | Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.31% | 177M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- ACHV Stock
- News Achieve Life Sciences, Inc.
- Achieve Life Sciences Receives US Patent for New Formulation of Cytisinicline